Treatment with platinum-based chemotherapy and bevacizumab led to complete remission and long-term survival in a patient with uterine cancer-induced pulmonary tumor thrombotic microangiopathy.
Case Report (n=1)
Can platinum-based chemotherapy and bevacizumab improve survival in a patient with uterine cancer-induced pulmonary tumor thrombotic microangiopathy?
Combination chemotherapy including molecular targeted therapies like bevacizumab may be an effective treatment option for cancer-induced pulmonary tumor thrombotic microangiopathy presenting with pulmonary hypertension.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare but fatal cancer-related disease. Owing to its non-specific findings, aggressive course, and lack of established treatment guidelines, only a few cases of antemortem diagnosis in long-term survivors have been reported. We aimed to report a case of uterine cervical cancer induced PTTM that was suspected based on pulmonary hypertension and successfully treated using combination chemotherapy despite of delayed diagnose. It is important to be aware that PTTM should be suspected when respiratory failure occurs in patients with unexplained pulmonary hypertension. Multidisciplinary treatments including molecular targeted therapies might be effective treatment options.
Taniguchi et al. (2021) conducted a case report in Uterine cancer-induced pulmonary tumor thrombotic microangiopathy (PTTM) (n=1). Platinum-based chemotherapy and bevacizumab was evaluated on Survival and remission. Treatment with platinum-based chemotherapy and bevacizumab led to complete remission and long-term survival in a patient with uterine cancer-induced pulmonary tumor thrombotic microangiopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: